Andrew R Crow
From Wikipedia, the free encyclopedia
| This article may not meet the general notability guideline or one of the following specific guidelines for inclusion on Wikipedia: Biographies, Books, Companies, Fiction, Music, Neologisms, Numbers, Web content, or several proposals for new guidelines. If you are familiar with the subject matter, please expand or rewrite the article to establish its notability. The best way to address this concern is to reference published, third-party sources about the subject. If notability cannot be established, the article is more likely to be considered for redirection, merge or ultimately deletion, per Wikipedia:Guide to deletion. This article has been tagged since May 2008. |
 |
The creator of this article, or someone who has substantially contributed to it, may have a conflict of interest regarding its subject matter. |
Andrew R. Crow is a Canadian scientist. He discovered the mechanism of action of Intravenous Immunoglobulin (IVIg) in the treatment of autoimmune disease[1] and, based on this substantial discovery, has developed new replacement therapies for IVIg.
Subsequently, his work in the field of medical research garnered Crow the Ontario Premier's Award for Technology in 2006.[2]
Crow graduated from Seneca College's Biological Research Technology Programme,[3] in 1988 and is a Senior Research Assistant with the Canadian Blood Services[4], located at St. Michael's Hospital.[5]
[edit] External links
- For a list of Crow's publications, see [2].
[edit] References
- ^ Nature Medicine 12, 688 - 692 (2006); Nature Protocols 10.1038/nprot.2006.153 (2006))
- ^ http://www.thecouncil.on.ca/files/pdfs/PremiersRecipients2006_E.pdf
- ^ Seneca College - Toronto, Canada.- Home
- ^ Canadian Blood Services - Société canadienne du sang
- ^ [1].
